ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Avista boosts drug active capacity

by Rick Mullin
November 20, 2017 | APPEARED IN VOLUME 95, ISSUE 46

Credit: Avista
One of three new 200-L Pfaudler reactors paired with GL Filtration dryers at Avista's facility.

Avista Pharma Solutions has doubled active pharmaceutical ingredient (API) production capacity at its Longmont, Colo., site. As part of the project, the company upgraded three API manufacturing suites and added a fourth. Avista was formed in 2015 when Ampersand Capital Partners combined Array BioPharma’s chemistry facility in Longmont with Scynexis’s contract R&D assets in Research Triangle Park, N.C., and Accuratus Lab Services in Eagan, Minn.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment